Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S., Significantly Expanding Its Innovative Portfolio

RYALTRIS^® is Glenmark's first innovative product introduced into the U.S. market

ELMWOOD PARK, N.J., April 1, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced that it will manage end-to-end commercialization and distribution for RYALTRIS^® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg* per spray in the United States, effective April 1, 2026.

This marks a meaningful step in Glenmark's continued expansion in the region with a sustainable approach to building a strong, direct commercial U.S. based presence.

RYALTRIS^® was launched in the United States in 2022 and is approved by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of symptoms associated with Seasonal Allergic Rhinitis (SAR) in adults and paediatric patients 12 years of age and older¹. It is a fixed-dose combination nasal spray that brings together olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) in a single formulation. The product is supplied as a 240-metered spray nasal suspension.

Seasonal Allergic Rhinitis affects millions of patients across the United States and remains an area where symptom control and treatment adherence continue to be important considerations. By combining two established therapies in one formulation, RYALTRIS^® offers a convenient treatment option¹ aligned with evolving patient and physician preferences.

Glenmark will directly lead brand strategy, market access, and customer engagement for RYALTRIS^® in the U.S. This allows for more focused execution, closer alignment with healthcare providers and greater responsiveness to market needs.

Commenting on the development, Marc Kikuchi, President & Business Head, North America said, "The commercialization by Glenmark for RYALTRIS^® in the United States is an important step forward for the growth of our company. It allows us greater operational direction in how we engage the market and support healthcare providers and patients across the nation. Today's announcement also marks a significant moment in our broader effort to strengthen our innovative businesses in the U.S. and build a more direct, sustainable commercial presence over time."

RYALTRIS^® is already approved in key markets including the United States, European Union, United Kingdom, Australia, South Korea, Russia and China. In FY26, RYALTRIS^® was launched in 11 additional markets, expanding its presence to 55 countries worldwide.

*Calculated on the anhydrous basis
¹RYALTRIS^® Nasal Spray approved prescribing information, Glenmark Specialty SA, Switzerland.
Please click here to view full prescribing information, including Important Safety Information.
For additional information about RYALTRIS^® and how to access, please visit us.ryaltris.com.
RYALTRIS is a registered trademark of Glenmark Specialty SA.

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a global, research‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.

Logo: https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg

SOURCE Glenmark Pharmaceuticals